Keros Therapeutics Inc. Common Stock (KROS)
Stock · NASDAQ · Health Care
$10.68as of 10/16/2026
Price chart
Active signals
KROS Signal Track Record
How signals performed across all stocks →What KROS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -0.9% | 49% | September 24, 2026 |
| Bollinger Band Breakout | 27 | -2.8% | 37% | October 9, 2026 |
| Bollinger Band BreakdownActive now | 18 | -2.7% | 33% | May 15, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -1.3% | 46% | February 18, 2026 |
| Any 20-session window (baseline) | +1.0% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 92
- Website
- www.kerostx.com/
Fundamentals
- 1-day range
- $10.98$11.4
- Market cap
- $211.16M
- P/E (trailing)
- —
- P/E (forward)
- -1.68
- EPS (trailing)
- $-3.70
- Dividend yield
- —
- Beta
- 1.20
- Avg. volume
- 191.8K
How Keros Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 4, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Keros Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- KROSKeros Therapeutics Inc. Common Stock$10.66▼ 3.96%Market cap $211.16MP/E —$9.69$22.55
- MSLESatellos Bioscience Inc. Common Stock$6.46▼ 5.56%Market cap $209.77MP/E —$7.56$18.98
- GLSIGreenwich LifeSciences Inc. Common Stock$14.55▼ 5.03%Market cap $209.02MP/E —$7.78$34.1
- NERVMinerva Neurosciences Inc Common Stock$2.35▼ 2.89%Market cap $206.85MP/E —$2.31$12.46
- ANTXAN2 Therapeutics Inc. Common Stock$3.38▼ 6.11%Market cap $218.98MP/E —$1$7.19
- SIGASIGA Technologies Inc. Common Stock$3.17▼ 0.63%Market cap $223.78MP/E —$2.83$8.55
- IMUXImmunic Inc. Common Stock$6.97▼ 1.83%Market cap $198.06MP/E —$5.06$17.43
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KROS Keros Therapeutics Inc. Common Stock | $211.16M | — | $10.66 | ▼ 3.96% | $9.69$22.55 |
| MSLE Satellos Bioscience Inc. Common Stock | $209.77M | — | $6.46 | ▼ 5.56% | $7.56$18.98 |
| GLSI Greenwich LifeSciences Inc. Common Stock | $209.02M | — | $14.55 | ▼ 5.03% | $7.78$34.1 |
| NERV Minerva Neurosciences Inc Common Stock | $206.85M | — | $2.35 | ▼ 2.89% | $2.31$12.46 |
| ANTX AN2 Therapeutics Inc. Common Stock | $218.98M | — | $3.38 | ▼ 6.11% | $1$7.19 |
| SIGA SIGA Technologies Inc. Common Stock | $223.78M | — | $3.17 | ▼ 0.63% | $2.83$8.55 |
| IMUX Immunic Inc. Common Stock | $198.06M | — | $6.97 | ▼ 1.83% | $5.06$17.43 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?Yahoo · 10/7/2026
- KROS Begins Dosing in Phase II Study With Rinvatercept in DMDYahoo · 9/29/2026
- Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trialbenzinga · 9/29/2026
- Keros Therapeutics to Receive Additional Development Milestone Payment from Partner TakedaYahoo · 9/29/2026
- Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical TrialBenzinga · 9/29/2026
- Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMDYahoo · 9/28/2026
- Keros Therapeutics Doses First Patient In Phase 2 Clinical Study Of Rinvatercept In Patients With Duchenne Muscular DystrophyBenzinga · 9/28/2026
Insider Activity
Insider Actions →- Tanini Annita · August 18, 2026 · Sale1.2K @ $10.29
- Esther Cho · August 18, 2026 · Sale4.5K @ $10.29
- Lorena Raquel Lerner · August 18, 2026 · Sale3.6K @ $10.29
- Charles W. Newton · August 18, 2026 · Sale551 @ $10.3
- Jean Jacques Bienaime · August 17, 2026 · Buy1.0K @ $10.27
- Jean Jacques Bienaime · July 15, 2026 · Buy1.0K @ $10.61
- Anne Prener · July 1, 2026 · Grant14.9K
- Anne Prener · July 1, 2026 · Grant13.8K
- Jean Jacques Bienaime · June 15, 2026 · Buy1.0K @ $10.19
- Charles W. Newton · June 11, 2026 · Sale550 @ $10.04
- Julius Knowles · June 4, 2026 · Sale2.6K @ $10.73
- Nima Farzan · June 4, 2026 · Sale2.6K @ $10.73
- Alpna Seth · June 4, 2026 · Sale2.6K @ $10.72
- Julius Knowles · June 3, 2026 · Grant7.4K
- Julius Knowles · June 3, 2026 · Grant7.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 18.03M
- Total value held
- $195.30M
- Institutional holders
- 146
- Unknown2.41M
- Unknown1.36M
- Unknown831.4K
- Unknown759.2K
- Unknown724.9K
- Unknown706.1K
- Unknown689.2K
- Unknown681.5K
- Unknown626.6K
- Unknown590.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial
Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial. Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.